Hematológia–Transzfuziológia
Volume/Issue:
Volume 53: Issue 3
Folyadékbiopszia-vizsgálatok alkalmazási lehetőségei az onkohematológiában
Authors:
Ákos Nagy I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Ákos Nagy in
Current site
Google Scholar
PubMed Close
,
Bence Bátai I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Bence Bátai in
Current site
Google Scholar
PubMed Close
,
Laura Kiss I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Laura Kiss in
Current site
Google Scholar
PubMed Close
,
Anita Marx Természettudományi Kar, Immunológiai Tanszék, Eötvös Lóránd Tudományegyetem, Budapest

Search for other papers by Anita Marx in
Current site
Google Scholar
PubMed Close
,
László Imre Pinczés Általános Orvostudományi Kar, Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Debrecen

Search for other papers by László Imre Pinczés in
Current site
Google Scholar
PubMed Close
,
Gergő Papp I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Gergő Papp in
Current site
Google Scholar
PubMed Close
,
Imre Kacskovics Természettudományi Kar, Immunológiai Tanszék, Eötvös Lóránd Tudományegyetem, Budapest

Search for other papers by Imre Kacskovics in
Current site
Google Scholar
PubMed Close
,
Donát Alpár I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Donát Alpár in
Current site
Google Scholar
PubMed Close
, and
Csaba Bödör I. sz. Patológiai és Kísérleti Rákkutató Intézet, MTA-SE Lendület Molekuláris Onkohematológiai Kutatócsoport, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Csaba Bödör in
Current site
Google Scholar
PubMed Close
Pages:
144–156
Online Publication Date:
21 Oct 2020
Publication Date:
21 Oct 2020
Article Category:
Review Article
DOI:
https://doi.org/10.1556/2068.2020.53.3.3
Keywords:
liquid biopsy; circulating cell-free DNA; circulating tumor DNA; oncohematology; prognosis assessment; treatment monitoring;
Keywords (Hungarian):
folyadékbiopszia; keringő sejtmentes DNS; keringő tumor-DNS; onkohematológia; prognózisbecslés; terápiamonitorozás;
Open access

Absztrakt:

A molekuláris biológiai technikák utóbbi évtizedekben látott fejlődésének köszönhetően a vérplazmában keringő biomolekuláknak, így például a tumor eredetű sejtmentes DNS-fragmentumoknak is korábban elképzelhetetlen mélységű vizsgálata vált elérhetővé. A minimális invazivitással járó folyadékbiopsziás mintavétel metasztatikus tumorok esetében lehetővé teszi eltérő anatómiai lokalizációval megjelenő genetikai aberrációk egyidejű feltérképezését, azok nyomon követését, illetve a klonális evolúció következtében megjelenő további abnormalitások kimutatását is. Ebből következően számos, szolid tumorokat vizsgáló, folyadékbiopsziás mintavételt alkalmazó tanulmány jelent meg az utóbbi évtizedben, néhány entitás vonatkozásában pedig az eljárás már a rutindiagnosztikában is alkalmazásra került. Onkohematológiában az ebből a szempontból legintenzívebben kutatott megbetegedések közé a diffúz nagy B-sejtes limfóma, a Hodgkin-limfóma, illetve a plazmasejtes mielóma tartozik. Saját, illetve irodalmi adatok alapján a tumor eredetű sejtmentes DNS vizsgálata hasznos lehet a kezelést megelőző prognózisbecslésben, a célozható molekuláris eltérések azonosításában, a terápiás hatékonyság és a minimális reziduális betegség monitorozásában, valamint a terápiarezisztens klónok kimutatásában. Jelen összefoglaló közleményünkben a folyadékbiopszia-vizsgálatok onkohematológiai alkalmazásait tekintjük át.

Abstract:

Advances in molecular biology techniques during the past decades allowed for the scrutiny of tumor derived biomolecules, including circulating tumor DNA fragments at an unprecedented level. In case of metastatic tumors, the minimally invasive liquid biopsy sampling provides great opportunity to simultaneously detect and monitor genetic aberrations emerging at distinct anatomical sites, and to identify alterations associated with clonal evolution. Consequently, several studies have recently interrogated the utility of liquid biopsy in the analysis of solid tumors, with this approach already being incorporated into the diagnostic workflow of some diseases. In oncohematology, diffuse large B-cell lymphoma, Hodgkin lymphoma and multiple myeloma are the most intensively studied entities in this regard. Based on data previously published by our group and others, the investigation of circulating tumor DNA in hematology has a potential to convey invaluable prognostic information prior to treatment, to detect actionable genetic alterations, to monitor treatment efficacy and minimal residual disease as well as to identify therapy resistant clones. In this review, we provide an overview of the potential applications of liquid biopsy analysis in oncohematology.
  • 1

    Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014; 4: 650–661.

  • 2

    Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14: 531–548.

  • 3

    Fan HC, Blumenfeld YJ, Chitkara U, et al. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem. 2010; 56: 1279–1286.

  • 4

    Alix-Panabieres C, Pantel K. The circulating tumor cells: liquid biopsy of cancer. Klin Lab Diagn. 2014: 60–64.

  • 5

    Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018; 379: 1754–1765.

  • 6

    Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019; 20: 71–88.

  • 7

    Gremel G, Lee RJ, Girotti MR, et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol. 2016; 27: 1959–1965.

  • 8

    Russo M, Siravegna G, Blaszkowsky LS, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016; 6: 147–153.

  • 9

    Camus V, Jardin F. Cell-free DNA and the monitoring of lymphoma treatment. Pharmacogenomics 2019; 20: 1271–1282.

  • 10

    Darrah JM, Herrera AF. Updates on circulating tumor DNA assessment in lymphoma. Curr Hematol Malig Rep. 2018; 13: 348–355.

  • 11

    Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018; 36: 1631–1641.

  • 12

    Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6: 224ra24.

  • 13

    Kilgour E, Rothwell DG, Brady G, et al. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 2020; 37: 485–495.

  • 14

    Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83: 8604–8610.

  • 15

    Alcaide M, Yu S, Bushell K, et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem. 2016; 62: 1238–1247.

  • 16

    Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016; 57: 2171–2179.

  • 17

    Scherer F, Kurtz DM, Diehn M, et al. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood 2017; 130: 440–452.

  • 18

    Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017; 17: 209–215.

  • 19

    Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011; 9: 133.

  • 20

    Melani C, Wilson WH, and Roschewski M Liquid biopsy in non-Hodgkin’s lymphoma. Hematol Oncol. 2019; 37 Suppl 1: 70–74.

  • 21

    Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood 2016; 127: 3127–3132.

  • 22

    Kurtz DM. Prognostication with circulating tumor DNA: is it ready for prime time? Hematology Am Soc Hematol Educ Program 2019; 2019: 47–52.

  • 23

    Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high- throughput sequencing. Blood 2015; 125: 3679–3687.

  • 24

    Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015; 16: 541–549.

  • 25

    Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016; 8: 364ra155.

  • 26

    Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 2017; 129: 1947–1957.

  • 27

    Jin MC, Kurtz DM, Esfahani MS, et al. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. Journal of Clinical Oncology 2017; 35: 7507–7507.

  • 28

    Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 2016; 128: 185–194.

  • 29

    Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018; 36: 2845–2853.

  • 30

    Sworder B, Kurtz DM, Macaulay C, et al. Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-cells during axicabtagene ciloleucel therapy. Blood 2019; 134: 550–550.

  • 31

    van Oers MH, Tonnissen E, Van Glabbeke M, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010; 28: 2246–2252.

  • 32

    Roulland S, Kelly RS, Morgado E, et al. t(14;18) translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014; 32: 1347–1355.

  • 33

    Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 2005; 105: 3428–3433.

  • 34

    Mandigers CM, Meijerink JP, Mensink EJ, et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001; 98: 940–944.

  • 35

    Lambrechts AC, Hupkes PE, Dorssers LC, et al. Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin’s lymphoma during first remission. J Clin Oncol. 1994; 12: 1541–1546.

  • 36

    Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807.

  • 37

    Sarkozy C, Huet S, Carlton VE, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017; 8: 8765–8774.

  • 38

    Delfau-Larue MH, van der Gucht A, Dupuis J, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv. 2018; 2: 807–816.

  • 39

    Bodor C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122: 3165–3168.

  • 40

    Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46: 176–181.

  • 41

    Bátai B, Lévai D, Gaál-Weisinger J, et al. New perspective in the personalized medicine of follicular lymphoma – Targeting the EZH2 histon methyltransferase. Hematológia−Transzfuziológia 2018; 51: 61–70.

  • 42

    FDA, FDA granted accelerated approval to tazemetostat for follicular lymphoma. 2020: https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma.

  • 43

    Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Blood 2019; 134: 123–123.

  • 44

    McDonald A, Thomas E, Daigle S, et al. Updated report on identification of molecular predictors of tazemetostat response in an ongoing NHL phase 2 study. Blood 2018; 132: 4097–4097.

  • 45

    Nagy A, Batai B, Balogh A, et al. Quantitative analysis and monitoring of EZH2 mutations using liquid biopsy in follicular lymphoma. Genes (Basel). 2020; 11.

  • 46

    Fontanilles M, Marguet F, Bohers E, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017; 8: 48157–48168.

  • 47

    Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018; 109: 225–230.

  • 48

    Watanabe J, Natsumeda M, Kanemaru Y, et al. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma 2019; 60: 3587–3589.

  • 49

    Zorofchian S, Lu G, Zhu JJ, et al. Detection of the MYD88 p.L265P mutation in the CSF of a patient with secondary central nervous system lymphoma. Front Oncol. 2018; 8: 382.

  • 50

    Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, et al. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma. Br J Haematol. 2019; 185: 974–977.

  • 51

    Hickmann AK, Frick M, Hadaschik D, et al. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer. 2019; 19: 192.

  • 52

    Bobillo S, Crespo M, Escudero L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica 2020.

  • 53

    Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 2019; 133: 436–445.

  • 54

    Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271–2278.

  • 55

    Cheminant M, Derrieux C, Touzart A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016; 101: 336–345.

  • 56

    Roschewski MJ, Melani CJ, Pittaluga S, et al. Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma. Journal of Clinical Oncology 2018; 36: 7576–7576.

  • 57

    Lakhotia R, Melani C, Pittaluga S, et al. Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma. Blood 2018; 132: 147–147.

  • 58

    Agarwal R, Chan YC, Tam CS, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25: 119–129.

  • 59

    Pizzi M, Margolskee E, Inghirami G. Pathogenesis of peripheral T-cell lymphoma. Annu Rev Pathol. 2018; 13: 293–320.

  • 60

    Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, et al. Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma. Ann Hematol. 2017; 96: 1471–1475.

  • 61

    Sun P, Chen C, Xia Y, et al. Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA. J Cancer. 2019; 10: 323–331.

  • 62

    Melani C, Pittaluga S, Yee L, et al. Next-generation sequencing based monitoring of circulating-tumor DNA in untreated peripheral T-cell lymphoma. Blood 2017; 130: 2728–2728.

  • 63

    Borchmann S, Engert A. The genetics of Hodgkin lymphoma: an overview and clinical implications. Curr Opin Oncol. 2017; 29: 307–314.

  • 64

    Jin MC, Schroers-Martin JG, Kurtz DM, et al. Noninvasive genotyping and monitoring of classical Hodgkin lymphoma. Blood 2018; 132: 2838–2838.

  • 65

    Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009; 20: 1408–1413.

  • 66

    Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2015; 2: e55–65.

  • 67

    Camus V, Stamatoullas A, Mareschal S, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 2016; 101: 1094–1101.

  • 68

    Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018; 131: 2413–2425.

  • 69

    Herrera AF, Kim HT, Kong KA, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016; 175: 841–850.

  • 70

    Oki Y, Neelapu SS, Fanale M, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015; 169: 689–693.

  • 71

    Pugh TJ. Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. Semin Hematol. 2018; 55: 38–40.

  • 72

    Waldschmidt JM, Anand P, Knoechel B, et al. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Semin Hematol. 2018; 55: 33–37.

  • 73

    Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia 2017; 31: 1695–1705.

  • 74

    Gerber B, Manzoni M, Spina V, et al. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica 2018; 103: e245–e248.

  • 75

    Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun. 2017; 8: 15086.

  • 76

    Mithraprabhu S, Morley R, Khong T, et al. Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia 2019; 33: 2022–2033.

  • 77

    Biancon G, Gimondi S, Vendramin A, et al. Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: A pilot study. J Mol Diagn. 2018; 20: 859–870.

  • 78

    Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018; 2: 2811–2813.

  • 79

    Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 2017; 102: 1105–111.

  • 80

    Rustad EH, Coward E, Skytoen ER, et al. Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica 2017; 102: 1266–1272.

  • 81

    Rajeev Krishnan S, De Rubis G, Suen H, et al. A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer J. 2020; 10: 37.

  • 82

    Manier S, Park J, Capelletti M, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018; 9: 1691.

  • 83

    Yeh P, Hunter T, Sinha D, et al. Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat Commun. 2017; 8: 14756.

  • 84

    Kiss R, Alpar D, Gango A, et al. Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Haematologica 2019; 104: e38–e41.

  • 85

    Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377: 454–464.

  • 86

    Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374: 2209–2221.

  • 87

    Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015; 314: 811–822.

  • 88

    Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424–447.

  • 89

    Krizsán S, Dénes Z, Gángó A, et al. Visszatérő genetikai eltérések vizsgálata akut myeloid leukémiában az új célzott terápiák tükrében. Hematológia–Transzfuziológia 2019; 52: 96–105.

  • 90

    Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131: 1275–1291.

  • 91

    Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994; 86: 774–779.

  • 92

    Quan J, Gao YJ, Yang ZL, et al. Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia. Int J Med Sci. 2015; 12: 17–22.

  • 93

    Ma W, Kantarjian H, Zhang X, et al. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark. 2009; 5: 51–58.

  • 94

    Nakamura S, Yokoyama K, Shimizu E, et al. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood 2019; 133: 2682–2695.

  • 95

    Suzuki Y, Tomita A, Nakamura F, et al. Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes. Cancer Sci. 2016; 107: 1329–1337.

  • 96

    Yeh P, Dickinson M, Ftouni S, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 2017; 129: 1685–1690.

  • 97

    Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34: 966–984.

  • 98

    Choi MY, Kato S, Wang HY, et al. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018; 19: 664–668.

  • Collapse
  • Expand
Cover Hematológia–Transzfuziológia
Hematológia–Transzfuziológia
Print ISSN:
1786-5913
Submit Your Manuscript

 

The author instructions are available in PDF.
Please, download the file from HERE.

 

 

  • Árpád ILLÉS (Debreceni Egyetem, főszerkesztő)
  • Csaba BÖDÖR (Semmelweis Egyetem, főszerkesztő-helyettes)
  • Judit DEMETER (Semmelweis Egyetem, főszerkesztő-helyettes)
  • Lajos GERGELY (Debreceni Egyetem, főszerkesztő-helyettes)
  • Imelda MARTON (Szegedi Tudományegyetem, főszerkesztő-helyettes)
  • Gábor MIKALA (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, főszerkesztő-helyettes)
  • Sándor FEKETE (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, emeritus főszerkesztő)
  • Hussain ALIZADEH (Pécsi Tudományegyetem, szerkesztő)
  • Hajnalka ANDRIKOVICS (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • Zita BORBÉNYI (Szegedi Tudományegyetem, szerkesztő)
  • Miklós EGYED (Somogy Megyei Kaposi Mór Oktató Kórház, szerkesztő)
  • Zsuzsanna FAUST (Pécsi Tudományegyetem, szerkesztő)
  • Béla KAJTÁR (Pécsi Tudományegyetem, szerkesztő)
  • Gergely KRIVÁN (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • András MASSZI (Országos Onkológiai Intézet, szerkesztő)
  • Tamás MASSZI (Semmelweis Egyetem, szerkesztő)
  • Zsolt György NAGY (Semmelweis Egyetem, szerkesztő)
  • Márk PLANDER (Vas Vármegyei Markusovszky Egyetemi Oktatókórház, szerkesztő)
  • György PFLIEGLER (Debreceni Egyetem, szerkesztő)
  • Péter REMÉNYI (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • Marienn RÉTI (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • János SINKÓ (Semmelweis Egyetem, szerkesztő)
  • László SZERAFIN (Szabolcs-Szatmár-Bereg Megyei Jósa András Oktatókórház, Nyíregyháza, szerkesztő)

Hematológia-Transzfuziológia Szerkesztőség
Dr. Illés Árpád
Debreceni Egyetem Klinikai Központ
Belgyógyászati Intézet B épület
4012 Debrecen, Nagyerdei krt. 98. Pf.: 20.
E-mail: illesarpaddr@gmail.com

  • CABELLS Journalytics

Hematológia-Transzfuziológia
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 100 EUR / 110 USD
Print + online subscription: 112 EUR / 124 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Hematológia-Transzfuziológia
Language Hungarian
Size A4
Year of
Foundation		 2004
Volumes
per Year		 1
Issues
per Year		 4
Founder Magyar Hematológiai és Transzfuziológiai Társaság
Founder's
Address		 Szent László Kórház, Hematológiai Osztály H-1097 Budapest, Hungary Gyáli út 5-7.
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 1786-5913 (Print)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2024 0 37 9
May 2024 0 39 11
Jun 2024 0 24 14
Jul 2024 0 45 4
Aug 2024 0 16 13
Sep 2024 0 35 1
Oct 2024 0 0 0